868 abstracts found.



Results filter

Efficacy and toxicities of a reduced dose sunitinib regimen in metastatic renal cell carcinoma

Year:

Session type:

Wei Seong Ooi1, Ko Ko Lin Thaw1, Valerie Khoo1, Vanessa Khoo1, Ravindran Kanesvaran1, Alexandre Chan3, Miah Hiang Tay1, Chee Keong Toh1, Min-Han Tan1

1National Cancer Centre Singapore, Singapore, 2National Cancer Centre Singapore, Singapore


Biological properties of the novel Chk1 inhibitor SAR-020106

Year:

Session type:

Paul Eve1, Mike Walton1, Angela Hayes1, Melanie Valenti1, Alexis De Haven Brandon1, Kathy Boxall1, Wynne Aherne1, Sue Eccles1, Gary Box1, Florence Raynaud1, David Williams2, Ian Collins1, John Reader2, Michelle Garrett1

1The Institute of Cancer Research, Surrey, UK, 2Sareum Ltd, Cambridge, UK


Combined targeting of Aurora B (AZD1152) and MEK1/2 (AZD6244) kinases leads to enhancement of anti-tumour effects in vivo

Year:

Session type:

Rajesh Odedra1, Simon P Heaton2, Armelle Logie1, Elizabeth Anderson1, Paul D Smith1, Robert W Wilkinson1

1AstraZeneca Pharmaceuticals, Macclesfield, UK, 2The Institute of Cancer Research, Sutton, UK


Phase I evaluation of radioimmunotherapy with 131I-CHT25 in patients with refractory IL2-receptor-expressing lymphomas

Year:

Session type:

Richard Begent2, Christopher McNamara2, Philip Ross1, James Ritchie1

1Cancer Research UK, London, UK, 2Royal Free Hospital, London, UK


Construction and characterisation of novel fusion toxin targeted to cancer (DT-SCF)

Year:

Session type:

Sirisha Potala, Rama Verma

Indian Institute of Technology Madras, Tamil Nadu, India


Gemcitabine with or without prophylactic weight-adjusted Dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

Year:

Session type:

Anthony Maraveyas1, Justin Waters2, Rajarshi Roy3, David Propper4, David Fyfe5, Fiona Lofts6, Eric Gardiner1, Joseph Sgouros1, Kevin Wedgwood1

1The Queens Centre for Oncology & Hematology, Hull, UK, 2Kent Oncology Centre, Maidstone Hospital, UK, 3Diana Princess of Wales Hospital, Grimsby, UK, 4St Bartholomews Hospital,, London, UK, 5Royal Lancaster Infirmary, UK, 6St. Georges Hospital Medical School, London, UK


Investigating the link between diet and prostate cancer within the ProtecT trial

Year:

Session type:

Catherine Jameson1, Athene Lane1, Pauline Emmett1, Liz Down1, Marta Tazewell1, Steven Oliver4, Freddie Hamdy3, David Neal2, Jenny Donovan1

1University of Bristol, UK, 2Cambridge University Addenbrookes Hospital, UK, 3University of Oxford, UK, 4University of York, UK


Unplanned hospital admissions as an early surrogate indicator of patient (pt) attrition in phase I trials

Year:

Session type:

Saoirse Dolly

The Institute of Cancer Research, London, UK


A comparison of the UCLA Integrated Staging System (UISS) model and the Leibovich score in survival prediction for patients with non-metastatic clear cell renal cell carcinoma

Year:

Session type:

Tiffany Tang1, Min Tun Nay1, Myo Oo Nay1, Kamalakannan Srimalan1, Caroline Choong2, Vanessa Khoo1, Valerie Khoo1, Tsung Wen Chong2, Puay Hoon Tan2, Min-Han Tan1

1The National Cancer Centre, Singapore, 2Singapore General Hospital, Singapore


A novel role for Nutlin-3 in the mammalian DNA-damage response

Year:

Session type:

Jane Valentine, Sonia Kumar, Abdeladim Moumen

St George's Hospital, University of London, UK


Page 1 of 871...25...Last »